Summit Therapeutics (SMMT) EPS (Weighted Average and Diluted) (2019 - 2025)
Historic EPS (Weighted Average and Diluted) for Summit Therapeutics (SMMT) over the last 5 years, with Q3 2025 value amounting to -$0.31.
- Summit Therapeutics' EPS (Weighted Average and Diluted) fell 28750.0% to -$0.31 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.25, marking a year-over-year decrease of 42083.33%. This contributed to the annual value of -$0.33 for FY2024, which is 6700.89% up from last year.
- Summit Therapeutics' EPS (Weighted Average and Diluted) amounted to -$0.31 in Q3 2025, which was down 28750.0% from -$0.76 recorded in Q2 2025.
- Over the past 5 years, Summit Therapeutics' EPS (Weighted Average and Diluted) peaked at -$0.01 during Q4 2023, and registered a low of -$0.76 during Q2 2025.
- For the 4-year period, Summit Therapeutics' EPS (Weighted Average and Diluted) averaged around -$0.15, with its median value being -$0.09 (2024).
- In the last 5 years, Summit Therapeutics' EPS (Weighted Average and Diluted) surged by 7500.0% in 2023 and then plummeted by 81328.01% in 2024.
- Over the past 4 years, Summit Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.04 in 2022, then skyrocketed by 75.0% to -$0.01 in 2023, then crashed by 813.28% to -$0.09 in 2024, then tumbled by 239.44% to -$0.31 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.31 for Q3 2025, versus -$0.76 for Q2 2025 and -$0.09 for Q1 2025.